Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf015 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Pirunthan Pathmarajah und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Dystrophica, Collagen Type VII. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCATS NIH HHS, Epidermolysis Bullosa Research Partnership.
Abstract (Originalsprache)
Background
Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic disorder caused by pathogenic variants in COL7A1.
Objectives
To determine the association between different COL7A1 variants and clinical disease severity in 236 North American patients with RDEB.
Methods
Published reports or in silico predictions were used to assess the impact of pathogenic variants in COL7A1 on type VII collagen (C7) protein function. Three impact categories were postulated: genotypes that would be likely to cause a low impact on C7 function (splice B/missense, missense/missense); a medium impact [premature termination codon (PTC)/splice B, splice A/splice B, PTC/missense, splice A/missense, splice B/splice B]; and a high impact (PTC/PTC, PTC/splice A, splice A/splice A). Splice A variants are predicted to cause downstream PTCs, while splice B variants cause in-frame exon skipping and are therefore less deleterious.
Results
The severity of functional impact was significantly associated with a history of gastrostomy tube placement, oesophageal dilation, hand surgery, anaemia, renal disease, chronic wounds, diffuse skin involvement and a history of squamous cell carcinoma. The odds of death were 3.5 time higher in the high-impact vs. medium-impact group (95% confidence interval 1.24–8.50; P = 0.02). Patients in the high-impact group had worse clinical outcomes.
Conclusions
Functional genotype categories are a feasible approach to risk-stratify patients based on predicted C7 function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.
ORCID-Profile: Jaron Nazaroff, Jean Y Tang
Förderung
- NIAMS NIH HHS
- NCATS NIH HHS
- Epidermolysis Bullosa Research Partnership
- and
- National Center for Advancing Translational Sciences
- CTSA
Zitieren
APA
Pathmarajah, P., Eid, E., Nazaroff, J., So, J., Mittal, V., Harris, N., Li, S., Lucky, A. W., Gorell, E. S., Peoples, K. G., Pope, E., Lara-Corrales, I., Paller, A. S., Wiss, K., Perman, M. J., Eichenfield, L. F., Levy, M. L., Morel, K. D., García-Romero, M. T., …, & Tang, J. Y. (2025). Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf015
Vancouver
Pathmarajah P, Eid E, Nazaroff J, So J, Mittal V, Harris N, et al. Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf015
BibTeX
@article{Pathmarajah2025,
author = {Pathmarajah, Pirunthan and Eid, Edward and Nazaroff, Jaron and So, Jodi and Mittal, Vaishali and Harris, Nicki and Li, Shufeng and Lucky, Anne W and Gorell, Emily S and Peoples, Kathleen G and Pope, Elena and Lara-Corrales, Irene and Paller, Amy S and Wiss, Karen and Perman, Marissa J and Eichenfield, Lawrence F and Levy, Moise L and Morel, Kimberly D and García-Romero, Maria T and McCuaig, Catherine C and Saber, Melissa and Marinkovich, M Peter and Oro, Anthony and Bruckner, Anna L and Tang, Jean Y},
title = {Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf015}
}
EUVIMED